Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary
Thornton, K., Kim, G., Maher, V. E., Chattopadhyay, S., Tang, S., Moon, Y. J., Song, P., Marathe, A., Balakrishnan, S., Zhu, H., Garnett, C., Liu, Q., Booth, B., Gehrke, B., Dorsam, R., Verbois, L., GVolume:
18
Language:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-12-0411
Date:
July, 2012
File:
PDF, 355 KB
english, 2012